Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas

AbstractThis observational study aimed to evaluate the prognostic significance of interim and final18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) responses to upfront autologous stem cell transplantation (ASCT) in patients with peripheral T cell lymphomas (PTCLs). A total of 118 patients, from two independent institutions, with newly diagnosed PTCLs were enrolled, and 96 of them were evaluated. PET/CT was assessed at diagnosis, and during and after the primary treatment. Clinical outcomes of interim and final PET/CT were compared between transplanted and non-transplanted patients. The responses of PET/CT were assessed based on visual analysis using the Deauville five-point scale (5-PS). Clinicopathological features of transplanted patients (n = 37) were similar to those of non-transplanted patients (n = 59). After a median follow-up of 60.8 months, only final PET/CT response based on 5-PS was the independent prognostic factor of survival outcome (P 
Source: Annals of Hematology - Category: Hematology Source Type: research

Related Links:

Conclusion: CTCL negatively affects patients' and caregivers' QoL. A considerable proportion of patients have no response or no sustainable response to current treatments. PMID: 31958235 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
Cutaneous T cell lymphomas represent a heterogenous group of lymphoproliferative disorders defined by clonal proliferation of T cells present in the skin. The latest WHO classification in 2016 and WHO-EORTC classification in 2018 has updated the classification of these entities based on the molecular profile. Research in the field of molecular genetics of CTCL has allowed a better understanding of the biology of these tumors and has helped to identify potential targets for therapy that can be tailored to individual patients. In this review, we discuss the latest developments in the molecular profile of CTCLs including biom...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   NK/T Cell Lymphoma Nos Interventions:   Drug: Sintilimab;   Drug: Lenalidomide Sponsor:   Beijing Tongren Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   T-Cell Lymphoma Relapsed & Refractory Interventions:   Drug: Copanlisib;   Drug: Romidepsin Sponsors:   Changchun Deng;   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   NK/T Cell Lymphoma Interventions:   Drug: IV Nivolumab;   Drug: IV Gemcitabine;   Drug: IV Cisplatin;   Drug: IV/PO Dexamethasone;   Drug: IV L-asparaginase Sponsors:   National Cancer Centre, Singapore;   Bristol-Myers Squibb Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   T-Cell Lymphoma Relapsed & Refractory Interventions:   Drug: Copanlisib;   Drug: Romidepsin Sponsors:   Changchun Deng;   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: January 2020Source: Journal of Comparative Pathology, Volume 174Author(s): C. Robveille, M. Kim, K. Langner, J. Stayt, C. Sharp
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
Radiotherapy is a cornerstone of both curative and palliative cancer care. However, radiotherapy is severely limited by radiation-induced toxicities. If these toxicities could be reduced, a greater dose of radiation could be given therefore facilitating a better tumor response. Initial pre-clinical studies have shown that irradiation at dose rates far exceeding those currently used in clinical contexts reduce radiation-induced toxicities whilst maintaining an equivalent tumor response. This is known as the FLASH effect. To date, a single patient has been subjected to FLASH radiotherapy for the treatment of subcutaneous T-c...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   NK/T Cell Lymphoma Nos Interventions:   Drug: Sintilimab;   Drug: Lenalidomide Sponsor:   Beijing Tongren Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: CT Scan | Hematology | Lymphoma | PET Scan | Stem Cell Therapy | Stem Cells | Study | T-cell Lymphoma | Transplants